Journal
PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 36, Issue 2, Pages 230-231Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0000000000001396
Keywords
Fusarium; disseminated fungal infection; child; therapy; outcome
Categories
Funding
- Merck/MSD
- German Federal Ministry of Research and Education
- 3M
- Actelion
- Astellas
- AstraZeneca
- Basilea
- Bayer
- Celgene
- Cubist/Optimer
- Duke University [NIH UM1AI104681]
- Genzyme
- Gilead
- GSK
- Leeds University
- Miltenyi
- NanoMR
- Pfizer
- Quintiles
- Scynexis
- Viropharma
- Astellas Pharma
- DaVolterra
- Gilead Sciences
Ask authors/readers for more resources
Disseminated fusariosis is a rare disease, and data are scant in pediatric patients. In the FungiScope registry, we identified 10 children with disseminated fusariosis between 2006 and 2015. Our analysis of the largest pediatric case series reported to date adds pediatric-specific experience to the management of this opportunistic infection in children.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
